Pharming extends Joenja approval to younger children in the U.K.
The U.K. regulator has approved Joenja for eligible children aged 4 to 11. The decision broadens access, but Pharming has not quantified the additional patient or revenue opportunity.
The U.K. Medicines and Healthcare products Regulatory Agency has extended Joenja’s approval to children aged 4 to 11 with activated PI3K delta syndrome, or APDS, who weigh at least 27 kilograms. The oral medicine was already approved in the U.K. for eligible adults and adolescents aged 12 and older. Pharming expects it to become available to the newly covered group in February 2027.
APDS is a rare genetic immune disorder that can cause recurrent infections and immune dysregulation. Joenja inhibits PI3K delta, a pathway that is overactive in people with the condition. The regulator’s decision was supported by Pharming’s paediatric programme and additional pharmacology and safety assessments. The company said leniolisib was generally well tolerated in patients aged four and above.
The approval matters because it converts part of Pharming’s paediatric development work into an expanded commercial label. It also follows a U.S. approval in September for the same age and weight group, while Japan permits treatment from age four. This gives Pharming another route to expand Joenja across ages and countries rather than relying only on diagnosis growth in the existing population.
The size of the commercial effect remains unclear. Pharming did not disclose how many U.K. children meet the age, weight and diagnosis criteria, what reimbursement will be, or how quickly NHS access will translate into treatment. February is an expected availability date, not a revenue forecast. The next useful evidence will be patient uptake and Joenja sales after the expanded indication becomes accessible.
